Michael Seiden

Michael V. Seiden, M.D., PhD, is an oncologist and healthcare executive with 30 years of experience spanning a variety of clinical, research, and operational roles. He currently serves as an advisor or Board member for a variety of small to mid-size early-stage companies mostly centered around cancer and specialty care. He is currently a Board Member for Glide Health, Medicom Technologies, and Nemucore Medical Innovations and advises several oncology companies including Grail, EQRX, Blue Note Therapeutics, and other venture back companies Previous Board roles have included Next Oncology and Medfusion prior to its sale to Quest. He also serves as a Board Member for non-profit organizations including the Damon Runyon Cancer Research Foundation and Lisa’s Army.

His previous operational roles include serving as the President of The US Oncology Network, the largest collection of community-based oncology care practices in the US, and a leader in the delivery of value-based oncology care and community-based clinical research. Previously, Dr. Seiden served as the senior vice president and Chief Medical Officer of The US Oncology Network and McKesson Specialty Health. Before joining The Network, he served as CEO, President, and Cancer Center Director of Fox Chase Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, research facility, and hospital in Philadelphia. Prior to Fox Chase, Dr. Seiden spent many years practicing oncology at Massachusetts General Hospital and Harvard Medical School, where he also served as Chief of the Cancer Center Clinical Research Unit as well as the program director for the Gynecologic Oncology Research Program for the Dana Farber/Harvard Cancer Center.